Recent progress and structural analyses of domain-selective BET inhibitors

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations

Abstract

Epigenetic mechanisms for controlling gene expression through heritable modifications to DNA, RNA, and proteins, are essential processes in maintaining cellular homeostasis. As a result of their central role in human diseases, the proteins responsible for adding, removing, or recognizing epigenetic modifications have emerged as viable drug targets. In the case of lysine-ε-N-acetylation (Kac), bromodomains serve as recognition modules (“readers”) of this activating epigenetic mark and competition of the bromodomain-Kac interaction with small-molecule inhibitors is an attractive strategy to control aberrant bromodomain-mediated gene expression. The bromodomain and extra-terminal (BET) family proteins contain eight similar bromodomains. These BET bromodomains are among the more commonly studied bromodomain classes with numerous pan-BET inhibitors showing promising anticancer and anti-inflammatory efficacy. However, these results have yet to translate into Food and Drug Administration-approved drugs, in part due to a high degree of on-target toxicities associated with pan-BET inhibition. Improved selectivity within the BET-family has been proposed to alleviate these concerns. In this review, we analyze the reported BET-domain selective inhibitors from a structural perspective. We highlight three essential characteristics of the reported molecules in generating domain selectivity, binding affinity, and mimicking Kac molecular recognition. In several cases, we provide insight into the design of molecules with improved specificity for individual BET-bromodomains. This review provides a perspective on the current state of the field as this exciting class of inhibitors continue to be evaluated in the clinic.

Original languageEnglish (US)
Pages (from-to)972-1018
Number of pages47
JournalMedicinal Research Reviews
Volume43
Issue number4
DOIs
StatePublished - Jul 2023

Bibliographical note

Funding Information:
Figures were created using BioRender and PyMol. Anand Divakaran was supported by the UMN Doctoral Dissertation Fellowship and NIH chemistry‐biology interface training grant (T32‐GM008700/T32‐GM132029‐01). William C.K. Pomerantz acknowledges the National Institute of General Medical Sciences MIRA award R35 GM140837‐01. Daniel A. Harki acknowledges financial support from the Minnesota Masonic Charities at UMN. The content is solely the responsibility of the authors and does not necessarily represent the official views of the supporting organizations.

Funding Information:
Figures were created using BioRender and PyMol. Anand Divakaran was supported by the UMN Doctoral Dissertation Fellowship and NIH chemistry-biology interface training grant (T32-GM008700/T32-GM132029-01). William C.K. Pomerantz acknowledges the National Institute of General Medical Sciences MIRA award R35 GM140837-01. Daniel A. Harki acknowledges financial support from the Minnesota Masonic Charities at UMN. The content is solely the responsibility of the authors and does not necessarily represent the official views of the supporting organizations.

Publisher Copyright:
© 2023 The Authors. Medicinal Research Reviews published by Wiley Periodicals LLC.

Keywords

  • BET-Bromodomain
  • domain-selectivity
  • epigenetics
  • reader domain

PubMed: MeSH publication types

  • Journal Article
  • Review
  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural

Fingerprint

Dive into the research topics of 'Recent progress and structural analyses of domain-selective BET inhibitors'. Together they form a unique fingerprint.

Cite this